Lazard Asset Management
CSBR icon

Lazard Asset Management’s Champions Oncology CSBR Stock Holding History

Lazard Asset Management’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,349
Closed -$9K – 1917
2025
Q2 		$9K Buy
+1,349
New +$9.52K ﹤0.01% 2172

Other funds holding CSBR

BMC
Battery Management Corp Boston, Massachusetts $426M AUM 21.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Lazard Asset Management's CSBR Position: Q3 2025 in Review

Lazard Asset Management sold out of Champions Oncology (CSBR) in Q3 2025, closing a stake of 1,349 shares — an estimated $9K sold.

Lazard Asset Management first reported a position in CSBR in Q2 2025 and held it in 1 quarter. The position peaked at $9K in Q2 2025. 27 funds tracked by Wall St. Rank hold CSBR as of Q3 2025.

  • Lazard Asset Management reported no remaining Champions Oncology position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 1,349 Champions Oncology shares in Q3 2025, an estimated $9K.
  • Lazard Asset Management first reported a position in Champions Oncology in Q2 2025 and held it in 1 quarter.
  • Lazard Asset Management's Champions Oncology position peaked at $9K in Q2 2025.
  • 27 funds tracked by Wall St. Rank held Champions Oncology as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.